A clinical study to compare the ayurvedic medicine Medhavati with allopathic medicine sertraline for the treatment of Depression.

A Prospective, Randomised, Comparative clinical study to Evaluate the Efficacy and Safety of Ayurvedic Medicine Medha Vati & Allopathic Medicine Sertraline in the Management of Depression. - Medha Vati Sertraline Depression

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025741

Enrollment

120

Registered

2020-06-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: oral tablet sertraline: 50mg once in a day for 12 weeks depending on the improvement of symptoms Control Intervention1: oral tablet medhavati: 2 tablets twice daily to be taken post me

Eligibility

Inclusion criteria

Inclusion criteria: Patients newly diagnosed as Depression of age 20-60 years as per icd-10 criteria with written informed consent by the patients. The HAM-D will be used to assess the severity of Depression.

Exclusion criteria

Exclusion criteria: 1 Age less than 20 years and more than 60 years 2 Pregnant and lactating women 3 Major medical chronic disorders 4 Severe depression with psychotic features or suicidal risks 5 Patient who do not give consent for the study

Design outcomes

Primary

Measure	Time frame
Reduction In Depressive Symptoms In HAM-D ScoreTimepoint: 1 Month	—

Secondary

Measure	Time frame
Satisfactory Improvement In Depressive Symptoms In HAM-D ScoreTimepoint: 3 Months	—

Countries

India

Contacts

Public ContactDr Meenaxi Sharma

National institute of medical sciences and research, Jaipur

tusharjagawat@yahoo.com09928048586

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026